日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib

POIESIS:一项针对对鲁索替尼反应欠佳的JAK抑制剂初治骨髓纤维化患者的附加navtemadlin III期研究

Vachhani, Pankit; Yacoub, Abdulraheem; Rampal, Raajit; Bradley, Terrence; Harrison, Claire; Jain, Tania; Kuykendall, Andrew; Palandri, Francesca; Mascarenhas, John; Al-Ali, Haifa; Passamonti, Francesco; Rothbaum, Wayne; Verstovsek, Srdan; Heidel, Florian H

Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis

间接比较莫美替尼与费德拉替尼在骨髓纤维化患者中的安全性

Masarova, Lucia; Verstovsek, Srdan; Palandri, Francesca; Mesa, Ruben; Harrison, Claire; Sajeev, Gautam; Gorsh, Boris; Simpson, Ryan; Cho, Sang; Wang, Zhaohui; Ellis, Catherine; Conlon, Seán; Signorovitch, James

Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis

间接比较莫美替尼与帕克替尼治疗骨髓纤维化患者的安全性和贫血结局

Masarova, Lucia; Verstovsek, Srdan; Palandri, Francesca; Mesa, Ruben; Harrison, Claire; Dobi, Balázs; Gorsh, Boris; Wang, Zhaohui; Ellis, Catherine; Patnaik, Dwaipayan; Liu, Tom; Kapetanakis, Venediktos

A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial

一项针对既往接受过鲁索替尼治疗或不适合接受鲁索替尼治疗的骨髓纤维化患者的随机、双盲研究:一项 II 期试验的第二阶段,评估了辛喷曲辛α的疗效。

Verstovsek, Srdan; Talpaz, Moshe; Wadleigh, Martha; Isidori, Alessandro; Te Boekhorst, Peter; Savona, Michael R; Bose, Prithviraj; Pozdnyakova, Olga; Mesa, Ruben; El-Galaly, Tarec C; O'Sullivan, Jennifer; Gamel, Katia; Higgins, Brian; Katakam, Sudhakar; Todorov, Boyan; Trunzer, Kerstin; Harrison, Claire N

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib

从鲁索替尼立即过渡到莫美替尼治疗骨髓纤维化患者的临床结果

Mesa, Ruben; Verstovsek, Srdan; Platzbecker, Uwe; Gupta, Vikas; Lavie, David; Giraldo, Pilar; Recher, Christian; Kiladjian, Jean-Jacques; Oh, Stephen T; Gerds, Aaron T; Devos, Timothy; Passamonti, Francesco; Vannucchi, Alessandro M; Egyed, Miklos; Lech-Maranda, Ewa; Pluta, Andrzej; Nilsson, Lars; Shimoda, Kazuya; McLornan, Donal; Kawashima, Jun; Klencke, Barbara; Huang, Mei; Strouse, Bryan; Harrison, Claire

Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study

索他西普治疗骨髓纤维化贫血:一项研究者发起的II期研究

Bose, Prithviraj; Masarova, Lucia; Pemmaraju, Naveen; Bledsoe, Sharon D; Daver, Naval G; Jabbour, Elias J; Kadia, Tapan M; Estrov, Zeev; Kornblau, Steven M; Andreeff, Michael; Jain, Nitin; Cortes, Jorge E; Borthakur, Gautam; Alvarado, Yesid; Richie, Mary Ann; Dobbins, Mackenzie H; McCrackin, Selene A; Zhou, Lingsha; Pierce, Sherry A; Wang, Xuemei; Pike, Allison M; Garcia-Manero, Guillermo; Kantarjian, Hagop M; Verstovsek, Srdan

Erratum to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia

更正:回顾性分析帕克替尼治疗骨髓纤维化和严重血小板减少症患者

Verstovsek, Srdan; Mesa, Ruben; Talpaz, Moshe; Kiladjian, Jean-Jacques; Harrison, Claire N; Oh, Stephen T; Vannucchi, Alessandro M; Rampal, Raajit; Scott, Bart L; Buckley, Sarah A; Craig, Adam R; Roman-Torres, Karisse; Mascarenhas, John O

miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2

miR-543通过靶向TET1和TET2调控骨髓纤维化的表观遗传图谱。

Fuentes-Mattei, Enrique; Bayraktar, Recep; Manshouri, Taghi; Silva, Andreia M; Ivan, Cristina; Gulei, Diana; Fabris, Linda; Soares do Amaral, Nayra; Mur, Pilar; Perez, Cristina; Torres-Claudio, Elizabeth; Dragomir, Mihnea P; Badillo-Perez, Adriana; Knutsen, Erik; Narayanan, Pranav; Golfman, Leonard; Shimizu, Masayoshi; Zhang, Xinna; Zhao, Wanke; Ho, Wanting Tina; Estecio, Marcos Roberto; Bartholomeusz, Geoffrey; Tomuleasa, Ciprian; Berindan-Neagoe, Ioana; Zweidler-McKay, Patrick A; Estrov, Zeev; Zhao, Zhizhuang J; Verstovsek, Srdan; Calin, George A; Redis, Roxana S

Interferons in the treatment of myeloproliferative neoplasms

干扰素在骨髓增生性肿瘤治疗中的应用

Vachhani, Pankit; Mascarenhas, John; Bose, Prithviraj; Hobbs, Gabriela; Yacoub, Abdulraheem; Palmer, Jeanne M; Gerds, Aaron T; Masarova, Lucia; Kuykendall, Andrew T; Rampal, Raajit K; Mesa, Ruben; Verstovsek, Srdan

Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM

MOMENTUM 研究比较了接受莫美替尼治疗和达那唑治疗的骨髓纤维化患者的输血相关成本抵消和时间负担。

Masarova, Lucia; Verstovsek, Srdan; Liu, Tom; Rao, Sumati; Sajeev, Gautam; Fillbrunn, Mirko; Simpson, Ryan; Li, Weilong; Yang, Joseph; Le Lorier, Yvette; Gorsh, Boris; Signorovitch, James